Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman

Now for more on that healthc care space, let's bring in Evan Seager, the head of healthcare research over at Beimo Capital Markets. Evan, thank you very much for being here with us. Take us through the dynamic.I mean, GLP1s have been the focus for such a long time now. Is there anything that gets this competitive dynamic between Lily and Novo to close the gap a bit in the coming months and quarters. >> Well, first off, thank you for having me.And I think just today there's a lot of anticipation into this Al ...